Evogene Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Evogene de 35.1% y 62.2%, respectivamente.
Información clave
35.1%
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.7% |
| Tasa de crecimiento de los ingresos | 62.2% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 11 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 60 | -5 | N/A | N/A | 1 |
| 12/31/2025 | 32 | -17 | N/A | N/A | 1 |
| 12/31/2024 | 17 | -21 | N/A | N/A | 1 |
| 12/31/2023 | 6 | -24 | -22 | -22 | N/A |
| 9/30/2023 | 6 | -20 | -19 | -18 | N/A |
| 6/30/2023 | 2 | -23 | -22 | -21 | N/A |
| 3/31/2023 | 2 | -25 | -23 | -22 | N/A |
| 12/31/2022 | 2 | -27 | -25 | -24 | N/A |
| 9/30/2022 | 1 | -31 | -31 | -30 | N/A |
| 6/30/2022 | 1 | -32 | -29 | -28 | N/A |
| 3/31/2022 | 1 | -29 | -29 | -28 | N/A |
| 12/31/2021 | 1 | -28 | -26 | -25 | N/A |
| 9/30/2021 | 1 | -29 | -24 | -24 | N/A |
| 6/30/2021 | 1 | -26 | -23 | -22 | N/A |
| 3/31/2021 | 1 | -24 | -19 | -19 | N/A |
| 12/31/2020 | 1 | -23 | -20 | -20 | N/A |
| 9/30/2020 | 1 | -21 | -18 | -17 | N/A |
| 6/30/2020 | 1 | -21 | -18 | -17 | N/A |
| 3/31/2020 | 0 | -21 | -19 | -18 | N/A |
| 12/31/2019 | 1 | -18 | -19 | -18 | N/A |
| 9/30/2019 | 1 | -18 | -16 | -16 | N/A |
| 6/30/2019 | 2 | -18 | -16 | -16 | N/A |
| 3/31/2019 | 2 | -19 | -16 | -16 | N/A |
| 12/31/2018 | 2 | -21 | -16 | -15 | N/A |
| 9/30/2018 | 2 | -21 | -16 | -16 | N/A |
| 6/30/2018 | 2 | -21 | -16 | -15 | N/A |
| 3/31/2018 | 3 | -21 | -16 | -16 | N/A |
| 12/31/2017 | 3 | -21 | -17 | -16 | N/A |
| 9/30/2017 | 4 | -21 | N/A | -17 | N/A |
| 6/30/2017 | 5 | -21 | N/A | -16 | N/A |
| 3/31/2017 | 5 | -21 | N/A | -15 | N/A |
| 12/31/2016 | 7 | -20 | N/A | -12 | N/A |
| 9/30/2016 | 8 | -18 | N/A | -12 | N/A |
| 6/30/2016 | 9 | -17 | N/A | -11 | N/A |
| 3/31/2016 | 10 | -17 | N/A | -12 | N/A |
| 12/31/2015 | 11 | -17 | N/A | -12 | N/A |
| 9/30/2015 | 12 | -17 | N/A | -10 | N/A |
| 6/30/2015 | 12 | -17 | N/A | -9 | N/A |
| 3/31/2015 | 13 | -16 | N/A | -8 | N/A |
| 12/31/2014 | 15 | -15 | N/A | -9 | N/A |
| 9/30/2014 | 17 | -14 | N/A | -8 | N/A |
| 6/30/2014 | 18 | -12 | N/A | -7 | N/A |
| 3/31/2014 | 18 | -11 | N/A | -6 | N/A |
| 12/31/2013 | 15 | -9 | N/A | -5 | N/A |
| 9/30/2013 | 18 | -5 | N/A | -5 | N/A |
| 6/30/2013 | 18 | -4 | N/A | -1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (62.2% al año) de EVGN crezcan más rápidamente que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (62.2% al año) de EVGN crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de EVGN se prevé que sea elevada dentro de 3 años.